Federal Register / Vol. 65, No. 201 / Tuesday, October 17, 2000 / Notices 61345

is conserved among genetically

divergent strains of HEV, the

neutralizing monoclonal antibodies may

be useful in the diagnosis, treatment

and/or prevention of hepatitis E.

Furthermore, immunogens that

encompass this neutralization site may

be used in vaccination to effectively

prevent, and/or reduce the incidence of

HEV infection. Polypeptides containing

this neutralization site may be useful in

evaluating vaccine candidates for the

production of neutralizing antibodies to

HEV.

Viral Glycoprotein Subunit Vaccine

Richard Compans, Ranjit Ray, U.S.

Patent 4,790,987 issued 13 Dec 1988.

Licensing Contact: Peter Soukas; 301/

496–7056 ext. 268; e-mail:

soukasp@od.nih.gov

The present invention relates to a

vaccine composition useful in the

prevention of virus-caused disease

comprising as its active agent at least

one immunogenically effective amount

of immunogenic viral envelope

glycoprotein complexed with a lipid.

These subunit vaccine compositions are

useful for the prevention of viral

infections including influenza virus,

parainfluenza virus, herpes virus,

paramyxoviruses, rabies virus, and

human T-cell lymphotrophic viruses.

The patent also discloses a method for

preparing the vaccine compositions. A

novel feature of the invention is the

utilization of a dialyzable detergent for

solubilization of the active component,

which allows a relatively simple

purification process on a large scale.

Thus, these vaccines are easier to

prepare than other glycoprotein subunit

vaccines and retain their antigenicity to

a greater extent than formalininactivated subunit vaccines.

Dated: October 5, 2000.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer,

National Institutes of Health.

[FR Doc. 00–26585 Filed 10–16–00; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Center for Research

Resources; Notice of Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Center for

Research Resources Special Emphasis Panel

Comparative Medicine.

Date: October 24, 2000.

Time: 3 pm to 4 pm.

Agenda: To review and evaluate grant

applications.

Place: Office of Review, National Center for

Research Resources, 6705 Rockledge Drive,

Bethesda, MD 20892, (Telephone Conference

Call).

Contact Person: Sybil A. Wellstood, PhD,

Scientific Review Administrator, Office of

Review, National Center for Research

Resources, 6705 Rockledge Drive, MSC 7965,

Room 6018, Bethesda, MD 20892–7965, 301–

435–0814.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.306, Comparative Medicine,

93.306; 93.333, Clinical Research, 93.333;

93.371, Biomedical Technology; 93.389,

Research Infrastructure, National Institutes of

Health, HHS)

Dated: October 5, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–26569 Filed 10–16–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Center for Research

Resources; Notice of Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Center for

Research Resources Special Emphasis Panel,

Comparative Medicine.

Date: October 27, 2000.

Time: 3 p.m. to 4 p.m.

Agenda: To review and evaluate grant

applications.

Place: Office of Review, National Center for

Research Resources, 6705 Rockledge Drive,

Bethesda, MD 20892, (Telephone Conference

Call).

Contact Person: Sybil A. Wellstood, PHD,

Scientific Review Administrator, Office of

Review, National Center for Research

Resources, 6705 Rockledge Drive, MSC 7965,

Room 6018, Bethesda, MD 20892–7965, 301–

435–0814.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.306, Comparative Medicine,

93.306; 93.333, Clinical Research, 93.333;

93.371, Biomedical Technology; 93.389,

Research Infrastructure, National Institutes of

Health, HHS)

Dated: October 4, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–26573 Filed 10–16–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Human Genome Research

Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings.

The meetings will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Human

Genome Research Institute Special Emphasis

Panel.

Date: October 27, 2000.

Time: 8 a.m. to 6 p.m.

Agenda: To review and evaluate grant

applications.